<DOC>
	<DOCNO>NCT01631539</DOCNO>
	<brief_summary>The purpose study assess feasibility chemoembolization DC Bead load Irinotecan combination Cetuximab 5FU/LV first line treatment wildtype KRAS unresectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab 5FU/LV First Line Patients With KRAS Wildtype mCRC</brief_title>
	<detailed_description>20 patient include . The duration trial approximately 24 month . Every 8 week tumour lesion assessment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Confirmed diagnosis stage IV KRAS wildtype colorectal adenocarcinoma , metastases predominantly liver ( ≥80 % tumor burden ) deem unresectable . 2 . Primary tumour treat complete surgical resection without evidence residual tumour 3 . Patients must least 1 measurable lesion ( RECIST criterion ) 4 . Performance status ECOG 01 5 . Aged ≥18 year 6 . Life expectancy &gt; 3 month 7 . No prior chemotherapy metastatic disease 8 . Hematologic function : WBC ≥ 3.0 x 10*9/L , platelet ≥ 100 x10*9/L 9 . Adequate organ function measure : Serum creatinine £ 1.5 x upper limit normal ( ULN ) Serum transaminase ( AST &amp; ALT ) £ 5 x ULN Bilirubin &gt; 1.5 time upper limit normal range 10 . Women child bear potential fertile men require use effective contraception ( negative βHCG woman childbearing age ) 11 . Signed , write informed consent 12 . Patients patent main portal vein 13 . Maximum liver involvement ≤60 % 1 . Presence CNS metastases 2 . Contraindications FU/LV , Irinotecan Cetuximab 3 . Active bacterial , viral fungal infection within 72 hour study entry 4 . Women pregnant breast feed 5 . Allergy contrast medium history severe hypersensitivity study drug . 6 . Presence another concurrent malignancy . Prior malignancy last 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix 7 . Any contraindication hepatic embolization procedure : portosystemic shunt hepatofugal blood flow severe atheromatosis 8 . Contraindication hepatic artery catheterization , patient severe peripheral vascular disease preclude catheterization 9 . Other significant medical surgical condition , medication treatment regimen , would place patient undue risk , would preclude safe use chemoembolization would interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>chemoembolization</keyword>
	<keyword>DC Bead™</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>5FU/LV</keyword>
	<keyword>KRAS</keyword>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>